Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Mar 31
Prestige Consumer Healthcare reported revenue of $1.1B in the fiscal year ended Mar 2026, down 4.3% from the year before. Operating income was $309M, an operating margin of 28.4%, and net income was $190M. Operating cash flow of $258M less capital expenditure of $11M left free cash flow of $246M. Net debt was $930M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1,087 | 1,128 | 1,125 | 1,138 | 1,089 |
| Cost of revenue | 466 | 502 | 501 | 503 | 493 |
| Gross profit | 621 | 625 | 624 | 634 | 596 |
| Operating income | 330 | −22.4 | 342 | 337 | 309 |
| Net interest incomeBanks | −64.3 | −69.2 | −67.2 | −47.6 | −42.3 |
| Interest expense | 64.3 | 4.4 | 5.2 | 1.8 | – |
| Pre-tax income | 262 | −93.9 | 276 | 284 | 257 |
| Income tax | 57.1 | −11.6 | 66.7 | 69.6 | 67.2 |
| Net income | 205 | −82.3 | 209 | 215 | 190 |
| Diluted EPS | 4.04 | −1.65 | 4.17 | 4.29 | 3.91 |
| Diluted shares | 50.8 | 49.9 | 50.2 | 50.1 | 48.7 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | 27.2 | 58.5 | 46.5 | 97.9 | 63.9 |
| Receivables | 139 | 167 | 177 | 194 | 192 |
| Inventory | 120 | 162 | 139 | 148 | 159 |
| Current assets | 293 | 392 | 375 | 448 | 431 |
| Net PP&E | 71.3 | 70.4 | 76.5 | 74.5 | 122 |
| Goodwill | 579 | 528 | 528 | 527 | 581 |
| Total assets | 3,671 | 3,354 | 3,318 | 3,402 | 3,494 |
| Payables | 55.8 | 62.7 | 39.0 | 18.9 | 22.8 |
| Current liabilities | 143 | 161 | 117 | 107 | 121 |
| Short-term debt | – | – | – | – | 0.0 |
| Long-term debt | 1,477 | 1,346 | 1,135 | 992 | 994 |
| Total liabilities | 2,093 | 1,907 | 1,663 | 1,567 | 1,607 |
| Shareholders' equity | 1,578 | 1,447 | 1,655 | 1,835 | 1,888 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating cash flow | 260 | 230 | 249 | 252 | 258 |
| Capital expenditure | 9.6 | 7.8 | 9.6 | 8.2 | 11.2 |
| Free cash flow | 250 | 222 | 239 | 243 | 246 |
| Depreciation & amortisation | 32.1 | 32.6 | 30.7 | 30.2 | 31.3 |
| Stock-based compensation | 9.0 | 12.4 | 14.0 | 11.2 | 10.8 |
| Acquisitions | 247 | 0.0 | 10.6 | 8.3 | 124 |
| Share buybacks | 0.0 | 50.0 | 25.0 | 51.5 | 156 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 3.8% | −0.2% | 1.1% | −4.3% |
| Operating income growth (YoY) | – | −106.8% | – | −1.7% | −8.1% |
| EPS growth (YoY) | – | −140.8% | – | 2.9% | −8.9% |
| Gross margin | 57.1% | 55.4% | 55.5% | 55.8% | 54.7% |
| Operating margin | 30.4% | −2.0% | 30.4% | 29.6% | 28.4% |
| Net margin | 18.9% | −7.3% | 18.6% | 18.9% | 17.5% |
| Return on equityBlank when equity is negative | 13.0% | −5.7% | 12.6% | 11.7% | 10.1% |
| ROCEEBIT ÷ (assets − current liabilities) | 9.4% | −0.7% | 10.7% | 10.2% | 9.2% |
| Free cash flow margin | 23.0% | 19.7% | 21.3% | 21.4% | 22.6% |
| Cash conversion (CFO ÷ net income) | 1.27x | −2.79x | 1.19x | 1.17x | 1.35x |
| Receivable days | 47 | 54 | 57 | 62 | 64 |
| Inventory days | 94 | 118 | 101 | 107 | 118 |
| Payable days | 44 | 46 | 28 | 14 | 17 |
| Interest cover | 5.13x | −5.09x | 65.9x | 187x | – |
| Debt ÷ equity | 0.94x | 0.93x | 0.69x | 0.54x | 0.53x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | 1,449 | 1,287 | 1,089 | 894 | 930 |
| Current ratio | 2.04x | 2.44x | 3.20x | 4.20x | 3.57x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.